From March next year, IAG Cargo is replacing its remaining A321 with wide-body B777-200s between London Heathrow and Tel Aviv. Th e twice daily service will be particularly beneficial to Israel’s fast-growing time and temperature-sensitive pharmaceuticals sector, according to IAG Cargo.

Customers will now benefit from a daily lift of 29 tonnes; representing a net increase of 2,500 tonnes in summer 2016 vs the same time this year, an increase of 72 per cent.

Israel is a major manufacturer of pharmaceutical products and its total pharmaceuticals market is expected to grow to US$2.3 billion by 2020.

Connecting through IAG Cargo’s London GDP approved Heathrow hub, Israeli drug companies’ benefit from access to 106 Constant Climate approved destinations, including extensive connections to the high-growth pharmaceuticals markets of Latin America.

“Tel Aviv is a thriving business centre and it’s also one of the most important regions for the manufacture of pharmaceuticals. Th rough the additional capacity delivered by the 777-200, we can now off er manufacturers in the region greater lift, helping them, as they look to grow their businesses,” said Alan Dorling, global head of Pharmaceuticals & Life Sciences at IAG Cargo.